Home » News

NEWS AND EVENTS

2022 Advanced Therapies Week at the Miami Convention Center

Access Biologicals is exhibiting at the 2022 American Society of Gene & Cell Therapy Annual Meeting in Miami, FL on January 25th through January 28th. “Advanced Therapies Week is the destination for anyone developing, investing or interested in cell and gene therapies and tissue engineered products. Throughout the week, we’ll be hosting a variety of networking events, focused roundtables and content sessions designed to help biotechs advance along their commercialization journey.” Visit us at booth 639 to meet our knowledgeable staff and learn about our cell culture and cell therapy product portfolios. If you’d like to arrange a meeting in advance, please email info@accessbiologicals.com. For more information and to register: 2022 Advanced Therapies Week

Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine

Abstract Seroconversion panels are an important tool for investigating antibody responses in acute and chronic phases of disease and development of serological assays for viral diseases including COVID-19. Globally it is anticipated that vaccines against SARS-CoV-2 will facilitate control of the current pandemic. The two COVID-19 seroconversion panels analyzed in this study were obtained from consenting donors with samples collected before vaccination with the mRNA-1273 vaccine (Moderna) and after the first and second doses of the vaccine. Panel samples were tested for antibodies to SARS-CoV-2 (IgG). Individual subjects with a positive response for anti-SARS-CoV2 IgG in their pre-vaccination samples showed a significantly enhanced response to the first vaccination. In older subjects, weaker immunological responses to the first injection were observed, which were overcome by the second injection. All subjects in the study were positive for anti-SARS-CoV-2 IgG after the second dose of vaccine. View full publication here

Access Biologicals offers panels for assay development, validation and qualification

Did you know Access Biologicals offers panels for assay development, validation and qualification?! For more information about our products, please visit: Panels, ​​​​COVID-19 Panels & Seroconversion Panels ANA (Antinuclear Antibody) Anti-CCP ((cyclic citrullinated peptide) antibodies in the blood)  APLS (antiphospholipid antibody syndrome) Celiac HSV1 & 2 Interference Panel MMRV (measles, mumps, rubella and varicella) SARS-CoV-2 Crossover panel ToRC Vasculitis Vitamin D COVID-19 Panels Normal, Healthy Serum (87 member) pre-pandemic COVID-19 positive single samples available in serum or K2 EDTA COVID-19 Seroconversion Panels HAV Seroconversion Panels Custom panels are available. Contact us about your needs and we can customize a panel for you. Many of our products are now available to purchase online: Shop here

Published article: Available COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays.

In collaboration, Grifols and Access Biologicals have published “Available COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays.” Abstract Seroconversion panels are an important tool for investigating antibody responses and developing serological assays. A seroconversion panel was generated from a single SARS-CoV-2 positive plasma donor over 87 days. This seroconversion panel was tested against 6 SARS-CoV-2 antibody tests (IgG, IgM, and total Ig). All test kits utilized recombinant antigens that are specific to SARS-CoV-2. The seroconversion panel showed IgG responses for SARS-CoV-2 after day 50. IgM levels peaked on day 50 (prior to IgG) and declined in subsequent samples. This seroconversion panel is a useful tool for validation of SARS-CoV-2 antibody assays.   View the article on ScienceDirect  

COVID-19 Vaccine Panels

Access Biologicals is now collecting samples from donors being vaccinated for COVID-19. 15 Subject Panel 3 samples per subject Sample 1: ≤ 2 days prior to the first vaccination Sample 2: ≤ 2 days prior to their second vaccination Sample 3: 13-15 days post their second vaccination • Some subjects with previous COVID infections • Serum only • 1mL samples • Methodology: DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG 30 Subject Panel 3 samples per subject Sample 1: ≤ 2 days prior to the first vaccination Sample 2: ≤ 2 days prior to their second vaccination Sample 3: 13-15 days post their second vaccination • Some subjects with previous COVID infections • Serum and K2 EDTA Plasma • 1mL samples • Methodology: DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG Contact us for more information or to request a custom panel.    

Hepatitis A (HAV) Seroconversion Panels are now available on Shopify

Access Biologicals is now offering Hepatitis A (HAV) Seroconversion Panels (Catalogue No: HAV001SCP) intended for use by diagnostic manufacturers and researchers during assay development, evaluation as well as troubleshooting HAV test methods. The HAV Seroconversion Panel consists of 23 members with each member containing 1 vial of 1.0 mL of human plasma. Panel members collected in this longitudinal series are from a single donor during the progression of an early HAV infection. This panel demonstrates the onset and decline of IgM and Ig total Hepatitis A virus antibodies and RNA titer over a period of 122 days. Panel members are undiluted, naturally occurring plasma samples collected in 4% sodium citrate. Units were aseptically filtered and no preservative has been added. All panel members are ready to use. Purchase this product on Shopify

View Product Portfolio